2014 News Releases

Webcast ImageWebcast
ASCEND Topline Results Conference Call (Replay)
02/25/14 at 8:00 a.m. ET
Keyword Search
Submit
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
03/13/14InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
BRISBANE, Calif., March 13, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering.  InterMune has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering.  InterMune estimates net proceeds from the offering to be approximately $233.0 million (assuming no exerc... 
Printer Friendly Version
03/12/14InterMune Announces Proposed Public Offering of Common Stock
BRISBANE, Calif., March 12, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering.  The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering.  All of the shares in the offering will be sold by InterMune.  The shares will be issued pursuant to a pro... 
Printer Friendly Version
02/25/14InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)
- Study Meets Primary and Both Key Secondary Endpoints - - Company to Conduct Conference Call and Webcast Today at 8:00 a.m. EST - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital... 
Printer Friendly Version
01/09/14InterMune Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue and Recent Business Highlights
- Q4'13 revenue of $25.6 million represents ninth consecutive quarter of Esbriet growth - - Last patient to complete treatment this month in Phase 3 ASCEND trial - - Strong progress on antifibrotic R&D pipeline - BRISBANE, Calif., Jan. 9, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013.  The company also provided updated 2013 expense guidance, highlighted recent progress in its commercial a... 
Printer Friendly Version
01/06/14InterMune to Present at J. P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 32nd Annual J. P. Morgan Healthcare Conference in San Francisco on January 13, 2014, at 12:00 Noon EST / 9:00 a.m. PST.  (Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) To access a live audio webcast of the presentation, investors and other interested parties may log on to the investo... 
Printer Friendly Version

You are now leaving the InterMune website. If you would like to continue, click Continue. Otherwise, click Cancel.
CancelContinue